Recommendation of the President – Forxiga (dapagliflozin)
On 22 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 7/2025 on the reimbursement of the medicinal product Forxiga (dapagliflozin), for the indication: type 2 diabetes, in patients using at least one antidiabetic drug, with insufficiently controlled diabetes and with a very high cardiovascular risk understood as: 1) confirmed cardiovascular disease, or 2) damage to other organs manifested by: proteinuria or left ventricular hypertrophy or retinopathy, or 3) the presence of 3 or more major risk factors from among those listed below: age ≥ 55 years for men, ≥ 60 years for women, dyslipidemia, hypertension, smoking, obesity